What price range was reported for the Beta Bionics (BBNX) insider share sale?

The weighted average sale price was $12.6071 per share, with individual trade prices ranging between $12.30 and $12.93. The filing notes that detailed information on the number of shares sold at each price is available upon request to the issuer or SEC staff.

Beta Bionics (BBNX) CPO sells 4,378 shares to cover RSU tax withholding

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a small share sale primarily for tax purposes. He sold 4,378 shares of Common Stock on June 2, 2026 at a weighted average price of $12.6071 per share, within a price range of $12.30 to $12.93.

According to the disclosure, the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units rather than a discretionary portfolio decision. After this transaction, Mensinger still directly owns 184,415 shares of Beta Bionics common stock.

Insider Trade Summary

Net Seller: 4,378 shares ($55,194)

Net Sell 1 txn

Insider Mensinger Mike

Role Chief Product Officer

Sold 4,378 shs ($55K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,378	$12.6071	$55K

Holdings After Transaction: Common Stock — 184,415 shares (Direct, null)

Footnotes (1)

The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 4,378 shares Weighted average sale price: $12.6071/share Sale price range: $12.30–$12.93/share +1 more

4 metrics

Shares sold 4,378 shares Common Stock sold on June 2, 2026

Weighted average sale price $12.6071/share Average price for reported sale

Sale price range $12.30–$12.93/share Range of prices for the transaction

Shares held after transaction 184,415 shares Direct holdings after sale

Key Terms

restricted stock units, weighted average sale price, open-market sale

3 terms

restricted stock units financial

"tax withholding obligations associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $12.6071"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/03/2026 - 06:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mensinger Mike

(Last)

(First)

(Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE

CALIFORNIA

92618

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Product Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/02/2026		S⁽¹⁾		4,378	D	$12.6071⁽²⁾	184,415	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Beta Bionics (BBNX) Chief Product Officer Mike Mensinger report in this Form 4?

Mike Mensinger reported a sale of 4,378 shares of Beta Bionics common stock. The transaction occurred on June 2, 2026, and was linked to tax withholding needs from restricted stock unit vesting rather than a discretionary open-market sale.

How many Beta Bionics (BBNX) shares did Mike Mensinger sell and at what price?

He sold 4,378 shares of Beta Bionics common stock at a weighted average price of $12.6071 per share. The reported sale prices ranged between $12.30 and $12.93 for the individual trades in this transaction.

Why did Mike Mensinger sell Beta Bionics (BBNX) shares in this transaction?

The filing states the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units. This indicates the sale was a mechanistic tax-related event, not primarily a discretionary decision to reduce his investment exposure.

How many Beta Bionics (BBNX) shares does Mike Mensinger hold after the reported sale?

After the sale, Mike Mensinger directly holds 184,415 shares of Beta Bionics common stock. This remaining position is significantly larger than the 4,378 shares sold, suggesting the transaction represented a relatively small portion of his overall holdings.

Was the Beta Bionics (BBNX) insider transaction an open-market sale?

The transaction is coded as an open-market sale, but the footnote clarifies the purpose was covering tax withholding on restricted stock unit vesting. That context makes it more of a routine tax event than a purely discretionary open-market sale decision.